May 1, 2025
| Today’s news and insights for biopharma leaders
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.
|
Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.
|
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.
|
Decades of pathogen research have led to breakthroughs like RSV vaccines from GSK, Pfizer, and Moderna. Explore the market potential and critical impact of innovation in preventive medicine in
|
The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core therapeutic areas” and “high value” programs.
|
Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and continuing a faster-than-expected drug launch.
|
News roundup
Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics production plant.
|
|
Amidst an industry-wide shift to digital solutions, GenAI is helping biopharma leaders create a frictionless contact center and deliver personalized experiences. Learn more in this playbook.
|
|
From Our Library
Webinar - on demand
Custom content for Premier Applied Sciences
|
Playbook
Custom content for MRN
|
Infographic
Custom content for UBC
|
| 
